The sale of Bioniq to Herbalife is not just a consolidation operation in the food supplement sector. Above all, it offers a point of reference on the evolution of exit structures in a post-correction environment, where valuation is no longer decreed, but is verified over time.
Behind a total amount of up to 138.5 million euros, the reality of the deal is more nuanced, with 50.75 million euros guaranteed, to which is added up to 87.75 million euros conditional on performance. In other words, more than 60% of the value remains to be demonstrated after signing.
The financial arrangement of the operation is so atypical that of the 55 million dollars announced, only 10 million are paid at closing, the balance being spread over five years.
A tiered valuation, indexed to execution
This type of structuring reflects a trend in M&A operations, where, just a few years ago, acquirers agreed to pay in advance for growth prospects, they now favor mechanisms that align valuation with actual performance.
In the case of Bioniq, this logic is all the more readable, as the company has raised around 27.2 million euros, including a Series B of 14.1 million euros in 2024, for a valuation of around 75.7 million euros. The current agreement introduces a significant gap between immediately realized value and potential value.
This differential is not only a matter of financial prudence and reflects a more structural question: to what extent can Bioniq’s value proposition, based on nutritional personalization based on biomarkers, be deployed on a large scale in an industrial environment?
Earn-out as a risk allocation instrument
The earn-out, which here is potentially greater than the guaranteed amount, functions as a mechanism for redistributing risk between seller and buyer. For the buyer, it limits initial exposure while retaining an option on future value creation. For the founder, it extends the liquidity horizon and conditions a significant part of the sale proceeds on the post-acquisition execution capacity.
This type of assembly introduces a form of ambiguity into the very notion of exit. The transaction does not mark a net exit, but rather a transition to a new phase, where value creation remains partly to be produced.
In this configuration, managerial continuity with Vadim Fedotov joining the Herbalife management team, becomes a central element. It makes it possible to maintain alignment between the initial promise and its operational realization.
In this configuration, managerial continuity with Vadim Fedotov joining the management team ofHerbalife helps maintain alignment between the initial promise and its operational realization. This situation is part of a common practice in operations of this type where the founder generally remains in office for two to three years, the time to ensure integration, secure the objectives conditioning the earn-out and transfer the intangible assets (product, teams, vision) within the acquiring organization.
There remains a potentially decisive unknown: Bioniq’s ability to maintain the active support of its highly visible business angels, foremost among them Cristiano Ronaldo and Diogo Dalot. Their role goes beyond that of financial investors because they constitute a relay of credibility and a vector of adoption. will they continue to embody the product promise within the Herbalife ecosystem?
Distribution and technology: an equation to validate
The strategic interest of the operation therefore rests on the apparent complementarity between the two players. Bioniq provides a data-driven technology layer, with more than 6 million biomarker data points, and a proprietary personalization engine. Herbalife, for its part, has a global distribution infrastructure covering 95 markets and relying on more than 2 million distributors.
A hollow reading of the venture market
Beyond the specific case of Bioniq, the operation is part of a movement to recompose the market. Since the readjustment of valuations that began in 2022, investors and buyers alike seem to favor more gradual approaches, where value creation is sequenced and conditioned.
This development is not limited to a logic of prudence, and also reflects a better integration of operational constraints into valuation models. Growth projections do not disappear, but they are now framed by mechanisms that test their robustness in real conditions.
In this context, startups positioned on hybrid models, combining technology, data and distribution, appear particularly concerned, and their value depends less on an isolated product than on their ability to fit into existing ecosystems.
It is precisely in this interval, between announced valuation and actually realized value, that a growing part of the exit economy now plays out. It remains to examine the effects on the distribution of value between founders and investors: the earn-out structuring, by conditioning a significant part of the price on future performance, can introduce imbalances, particularly when managers find themselves permanently constrained by objectives that they no longer fully control within the acquiring organization.
